Argenica Therapeutics (ASX:AGN) said the independent Data Safety Monitoring Board recommended that the phase two clinical trial of neuroprotective peptide drug candidate, ARG-007, in acute ischaemic stroke patients continue with no modification, according to a Thursday filing with the Australian bourse.
The board reviewed the safety data of the first 76 patients dosed in Argenica's phase two trial, which represents a review of 83% of patients in the study.
The board is an independent multidisciplinary committee consisting of an independent chairperson neurologist, two additional independent neurologists, and a biostatistician with relevant clinical trial experience.
Dosing is 86% complete, with 79 patients dosed in the phase two trial, with eight of the 10 activated hospitals having dosed patients, according to the filing. Dosing of all 92 patients is expected to be completed in the second quarter.
The firm's shares rose past 4% in recent trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。